---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004977"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:43:04.713728+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q2 ORLADEYO rev $156.8M (+45% YoY); net income $5.1M vs loss $12.7M

## Summary
- Q2 total revenue $163.4M (+50% YoY); ORLADEYO net rev $156.8M (+45% YoY).
- Operating income $29.8M (up from $8.8M); non-GAAP op income $57.0M (up from $21.9M).
- Net income $5.1M ($0.02 EPS) vs net loss $12.7M ($0.06 loss) in Q2 2024.
- Made additional $50M term debt paydown in July; plans to retire remaining $199M with proceeds from European ORLADEYO sale expected to close early Oct.
- Full-year 2025 ORLADEYO revenue guidance maintained at $580M-$600M; pipeline on track for data in two programs by year-end.

## SEC filing metadata
- accession: 0001171843-25-004977
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325004977/0001171843-25-004977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325004977/f8k_080425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004977
- JSON: https://secwatch.observer/filing/0001171843-25-004977.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.